Trial Profile
A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 27 Jul 2017 This trial has been discontinued the United Kingdom
- 04 Jul 2012 Planned number of patients changed from 636 to 978 as reported by European Clinical Trials Database.
- 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry)